8月17日，西维斯健康盘中下跌3.02%，报94.23美元/股，成交额2.01亿美元。
消息面上，公司此前发布二季度财报，虽然当季业绩大幅超出预期（调整后每股收益2.58美元，远超市场预期的1.85美元），并将全年调整后EPS指引上调至7.90至8.10美元区间，但管理层同时对2027年核心业务发出预警。公司高管明确表示，340B药品折扣计划带来的市场压力预计将在2027年对药房服务业务构成显著拖累，远期盈利前景的不确定性持续压制市场情绪。尽管多家机构维持买入评级并上调目标价，但投资者对远期增长预期的重新定价仍在进行中。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.